Type 2 diabetes mellitus continues to be a challenging disease to manage successfully. Beyond the first-line option metformin, there are a number of classes of medications from which to select. This article reviews the new sodium-glucose cotransporter 2 inhibitors canagliflozin and dapagliflozin, including their benefits, adverse effects, and potential place…
Sodium-glucose cotransporter type 2 (SGLT2) inhibitors such as canagliflozin and dapagliflozin have been approved for the treatment of type 2 diabetes mellitus. A PubMed search was conducted of the literature from April 1996 to August 2014 to identify all human studies related to SGLT2 inhibitors. Pertinent guidelines of experts and…
Membership grants access to journals, courses and a slew of premium benefits.
Please consider supporting us by choosing an option below:
View Membership Options Make A Tax-Deductable Donation
No Thanks, take me to the site and don't show me this again.